{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:12:55Z","timestamp":1776852775554,"version":"3.51.2"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.08.008","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T20:00:51Z","timestamp":1726344051000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6404-3793","authenticated-orcid":false,"given":"Alex H.","family":"Gifford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9779-2571","authenticated-orcid":false,"given":"Katherine","family":"Odem-Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Kloster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian P.","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8360-4405","authenticated-orcid":false,"given":"Gregory J.","family":"Omlor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-0415","authenticated-orcid":false,"given":"Susan L.","family":"Millard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory S.","family":"Sawicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-3512","authenticated-orcid":false,"given":"Kristin","family":"Riekert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Mayer-Hamblett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8611-7960","authenticated-orcid":false,"given":"David P.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.08.008_bib0001","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/thx.2009.125831","article-title":"Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function","volume":"65","author":"Amin","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2024.08.008_bib0002","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.08.008_bib0003","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M","article-title":"Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis","volume":"21","author":"Eng","year":"1996","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.08.008_bib0004","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa043891","article-title":"Mucus clearance and lung function in cystic fibrosis with hypertonic saline","volume":"354","author":"Donaldson","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.08.008_bib0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0140-6736(93)92297-7","article-title":"Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis","volume":"342","author":"Ranasinha","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.08.008_bib0006","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.08.008_bib0007","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/thx.50.4.333","article-title":"Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I","volume":"50","author":"Shah","year":"1995","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2024.08.008_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society"},{"key":"10.1016\/j.jcf.2024.08.008_bib0009","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/ppul.24178","article-title":"Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016","volume":"53","author":"Grosse","year":"2018","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.08.008_bib0010","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jcf.2019.10.025","article-title":"Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials","volume":"19","author":"Davies","year":"2020","journal-title":"J Cystic Fibrosis : Official J European Cystic Fibrosis Society"},{"key":"10.1016\/j.jcf.2024.08.008_bib0011","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jcf.2019.11.007","article-title":"Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy","volume":"19","author":"Gifford","year":"2020","journal-title":"J Cystic Fibrosis: Official J European Cystic Fibrosis Society"},{"key":"10.1016\/j.jcf.2024.08.008_bib0012","first-page":"26","article-title":"The cost of simplifying treatments for cystic fibrosis: Implications of the SIMPLIFY trial","volume":"30","author":"Gold","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jcf.2024.08.008_bib0013","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccm.2022.06.009","article-title":"Update on clinical outcomes of highly effective modulator therapy","volume":"43","author":"Gifford","year":"2022","journal-title":"Clinics in chest medicine"},{"key":"10.1016\/j.jcf.2024.08.008_bib0014","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.08.008_bib0015","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jcf.2021.08.014","article-title":"Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?","volume":"21","author":"Granger","year":"2022","journal-title":"J Cystic Fibrosis: Official J European Cystic Fibrosis Society"},{"key":"10.1016\/j.jcf.2024.08.008_bib0016","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jcf.2022.05.005","article-title":"Research letter: The impact of elexacaftor\/tezacaftor\/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis","volume":"21","author":"Song","year":"2022","journal-title":"J Cystic Fibrosis : Official J European Cystic Fibrosis Society"},{"key":"10.1016\/j.jcf.2024.08.008_bib0017","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/thoraxjnl-2017-210473","article-title":"The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers","volume":"73","author":"Rowbotham","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2024.08.008_bib0018","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chest.2022.07.008","article-title":"Treatment Preference Among People With Cystic Fibrosis: The Importance of Reducing Treatment Burden","volume":"162","author":"Cameron","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2024.08.008_bib0019","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/MCP.0000000000001006","article-title":"Chronic daily respiratory care needs in people with cystic fibrosis treated with highly effective cystic fibrosis transmembrane conductance regulator modulators","volume":"29","author":"Wajda","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jcf.2024.08.008_bib0020","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1513\/AnnalsATS.202010-1336SD","article-title":"Evaluating the impact of stopping chronic therapies after modulator drug therapy in cystic fibrosis: The SIMPLIFY clinical trial study design","volume":"18","author":"Mayer-Hamblett","year":"2021","journal-title":"Annals of the American Thoracic Society"},{"key":"10.1016\/j.jcf.2024.08.008_bib0021","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"The lancet Respiratory medicine"},{"key":"10.1016\/j.jcf.2024.08.008_bib0022","article-title":"Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: a retrospective review","author":"Guenther","year":"2023","journal-title":"Journal of Cystic Fibrosis : Official J European Cystic Fibrosis Society"},{"key":"10.1016\/j.jcf.2024.08.008_bib0023","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/S1569-1993(23)00488-5","article-title":"P113 Home reported outcomes (HERO-2) in people with cystic fibrosis taking elexacaftor\/tezacaftor\/ivacaftor: self-reported changes in use of chronic daily therapies at enrollment","volume":"22","author":"Ren","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.08.008_bib0024","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S1569-1993(23)00467-8","article-title":"P092 Preliminary observations of treatment and symptom reporting in the Home-Reported Outcomes in cystic fibrosis study (HERO-2)","volume":"22","author":"Brown","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.08.008_bib0025","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/1740774514547396","article-title":"The transitioning from trials to extended follow-up studies","volume":"11","author":"Drye","year":"2014","journal-title":"Clinical trials"},{"key":"10.1016\/j.jcf.2024.08.008_bib0026","series-title":"Patient follow-up, close-out, and post-trial follow-up. clinical trials: design, conduct and analysis","first-page":"159","author":"Meinert","year":"1986"},{"key":"10.1016\/j.jcf.2024.08.008_bib0027","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1569-1993(23)00465-4","article-title":"Treatment use among SIMPLIFY trial participants through 24 weeks of follow-up","volume":"22","author":"Gifford","year":"2023","journal-title":"Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society"},{"key":"10.1016\/j.jcf.2024.08.008_bib0028","first-page":"119","article-title":"Approximate Is Better than \"Exact\" for Interval Estimation of Binomial Proportions","volume":"52","author":"Agresti","year":"1998","journal-title":"The American Statistician"},{"key":"10.1016\/j.jcf.2024.08.008_bib0029","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/ije\/26.6.1323","article-title":"Regression models for ordinal responses: a review of methods and applications","volume":"26","author":"Ananth","year":"1997","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jcf.2024.08.008_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v015.i02","article-title":"The R Package geepack for Generalized Estimating Equations","volume":"15","author":"Halekoh","year":"2006","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jcf.2024.08.008_bib0031","first-page":"522","article-title":"Cystic fibrosis pulmonary guidelines: airway clearance therapies","volume":"54","author":"Flume","year":"2009","journal-title":"Respir Care"},{"key":"10.1016\/j.jcf.2024.08.008_bib0032","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.08.008_bib0033","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1186\/s13063-021-05866-6","article-title":"Methodological approaches for conducting follow-up research with clinical trial participants: a scoping review and expert interviews","volume":"22","author":"Signorell","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.jcf.2024.08.008_bib0034","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/bmjqs-2015-004315","article-title":"Coproduction of healthcare service","volume":"25","author":"Batalden","year":"2016","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.jcf.2024.08.008_bib0035","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","article-title":"Self-report measures of medication adherence behavior: recommendations on optimal use","volume":"5","author":"Stirratt","year":"2015","journal-title":"Transl Behav Med"},{"key":"10.1016\/j.jcf.2024.08.008_bib0036","series-title":"Encyclopedia of social measurement","first-page":"411","article-title":"Response Bias","author":"Graeff","year":"2005"},{"key":"10.1016\/j.jcf.2024.08.008_bib0037","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40471-020-00241-6","article-title":"Selection mechanisms and their consequences: understanding and addressing selection bias","volume":"7","author":"Smith","year":"2020","journal-title":"Current Epidemiol Reports"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324008397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324008397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:11:17Z","timestamp":1738275077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324008397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324008397"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.08.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}